The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
02 2021
Historique:
received: 03 12 2019
accepted: 21 08 2020
revised: 19 08 2020
pubmed: 16 9 2020
medline: 17 7 2022
entrez: 15 9 2020
Statut: ppublish

Résumé

Histiocytic sarcoma and tumors with dendritic cell differentiation (HDT) are uncommon neoplasms often with an aggressive clinical course that may occur in association with another hematologic malignancy or mediastinal germ cell tumor (secondary HDT, sHDT). Previous studies have shown mutations in the RAS/MAPK pathway in HDT and have demonstrated a clonal relationship between HDT and associated lymphoid malignancies through common translocations or identical immunoglobulin or T-cell receptor gene rearrangements. We performed whole exome sequencing on 16 cases of sHDT to further evaluate the spectrum of mutations that occur in sHDT in the context of an associated lymphoid malignancy, including cases associated with follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma, B- and T-cell acute lymphoblastic leukemia/lymphoma and peripheral T-cell lymphoma, NOS. In addition, we assessed the clonal relationship between the HDT and the associated lymphoid malignancy in three cases for which matched samples were available. We found mutations in RAS/MAPK pathway genes in 14/16 cases of sHDT associated with diverse mature and precursor B-cell and T-cell neoplasms, involving KRAS (8/16), BRAF (2/16), NRAS (2/16), MAP2K1 (1/16), and NF1 (1/16). In addition, we note that FL-associated sHDT frequently shares a similar mutational profile to the associated malignancy, identifying mutations in CREBBP or KMT2D in all cases and "aberrant" somatic hypermutation in 5/6 cases. Our study confirms the role of the RAS/MAPK pathway in the pathogenesis of sHDT, provides further evidence of a common neoplastic precursor and, in the case of FL, gives additional insight into the stage in lymphomagenesis at which transdifferentiation may occur.

Identifiants

pubmed: 32929178
doi: 10.1038/s41379-020-00673-x
pii: S0893-3952(22)00675-5
pmc: PMC9161669
mid: NIHMS1801979
doi:

Substances chimiques

Extracellular Signal-Regulated MAP Kinases EC 2.7.11.24
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-347

Subventions

Organisme : Intramural NIH HHS
ID : ZIA SC000550
Pays : United States
Organisme : Intramural NIH HHS
ID : ZID BC011959
Pays : United States

Références

Lancet Oncol. 2005 Jun;6(6):435-7
pubmed: 15925822
Blood. 2017 Jan 26;129(4):473-483
pubmed: 28064239
Blood. 2014 Nov 6;124(19):3016-9
pubmed: 25150293
Bioinformatics. 2012 Oct 15;28(20):2678-9
pubmed: 22914218
Cancer Discov. 2016 Feb;6(2):154-65
pubmed: 26566875
Blood. 2016 Nov 17;128(20):2475
pubmed: 27856472
Oncotarget. 2012 Nov;3(11):1308-19
pubmed: 23131835
Blood. 2008 Jun 15;111(12):5433-9
pubmed: 18272816
PLoS Comput Biol. 2020 Feb 13;16(2):e1007603
pubmed: 32053599
Immunity. 2006 Nov;25(5):731-44
pubmed: 17088084
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Hematol Oncol. 2015 Mar;33(1):23-30
pubmed: 24496723
N Engl J Med. 2018 May 17;378(20):1945-1947
pubmed: 29768143
Science. 2002 Jul 5;297(5578):110-3
pubmed: 12098702
Am J Surg Pathol. 2009 Jun;33(6):863-73
pubmed: 19145200
Leuk Lymphoma. 2010 May;51(5):802-12
pubmed: 20331331
Lancet Oncol. 2004 Apr;5(4):248-50
pubmed: 15050956
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Virchows Arch. 2017 Oct;471(4):467-489
pubmed: 28695297
Blood. 2014 Nov 6;124(19):3007-15
pubmed: 25202140
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Mod Pathol. 2011 Nov;24(11):1421-32
pubmed: 21666687
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Am J Surg Pathol. 2018 Feb;42(2):150-159
pubmed: 29194093
Nature. 2001 Jul 19;412(6844):341-6
pubmed: 11460166
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Haematologica. 2020 Apr;105(4):951-960
pubmed: 31439678
Blood. 2016 Aug 25;128(8):1093-100
pubmed: 27325104
Hum Pathol. 2016 Sep;55:39-43
pubmed: 27134111
Am J Clin Pathol. 2019 Sep 9;152(4):486-494
pubmed: 31172191
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Am J Surg Pathol. 2013 Jul;37(7):978-86
pubmed: 23759932
Pathobiology. 2014;81(4):199-205
pubmed: 25228298
Blood. 2013 Feb 28;121(9):1604-11
pubmed: 23297126
Leukemia. 2018 Mar;32(3):675-684
pubmed: 28804123
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Diagn Pathol. 2018 Oct 15;13(1):78
pubmed: 30322385
Mod Pathol. 2019 Jun;32(6):830-843
pubmed: 30626916
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25
pubmed: 25713363
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Bioinformatics. 2011 Jun 15;27(12):1691-2
pubmed: 21493652
Am J Surg Pathol. 2011 Mar;35(3):457-63
pubmed: 21317718
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Haematologica. 2010 Sep;95(9):1461-6
pubmed: 20421277
Stem Cell Reports. 2017 Feb 14;8(2):346-359
pubmed: 28111277
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Pediatr Blood Cancer. 2011 Feb;56(2):307-10
pubmed: 20973102
Leukemia. 2014 Sep;28(9):1937-40
pubmed: 24850291
Nat Genet. 2014 Feb;46(2):176-181
pubmed: 24362818
Cell. 2004 May 28;117(5):663-76
pubmed: 15163413
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626

Auteurs

Caoimhe Egan (C)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Justin Lack (J)

NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Shannon Skarshaug (S)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Thu Anh Pham (TA)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Zied Abdullaev (Z)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Liqiang Xi (L)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Svetlana Pack (S)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Stefania Pittaluga (S)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Elaine S Jaffe (ES)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Mark Raffeld (M)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. mraff@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH